...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Breast cancer research and treatment. >Adjuvant taxane-based chemotherapy for early stage breast cancer: a real-world comparison of chemotherapy regimens in Ontario
【24h】

Adjuvant taxane-based chemotherapy for early stage breast cancer: a real-world comparison of chemotherapy regimens in Ontario

机译：基于紫杉烷类辅助化疗的早期乳腺癌：安大略省化疗方案的现实比较

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The purpose of this study was to compare survival and risk of adverse events in women with early stage breast cancer (BC) treated with (1) doxorubicin (A), cyclophosphamide (C) + paclitaxel (P), (2) fluorouracil (F), epirubicin (E), cyclophosphamide (C) + docetaxel (D), or (3) dose-dense AC-P. Retrospective cohort study including 8462 women aged a parts per thousand yen18 years, with resected stage I-III BC, diagnosed between 2003 and 2009 in Ontario, identified through linkage of administrative databases. Primary outcome is overall survival (OS). Secondary outcomes are emergency room (ER) visits/hospitalizations, heart failure (HF), and leukemia. 4710 women were treated with FEC-D, 2065 with AC-P, and 1687 with dd AC-P. Adjusted 5-year OS was 92.1, 87.7, and 90.3 %, for each regimen, respectively (p = 0.0006). There was no difference in OS for FEC-D and dd AC-P in the propensity score-matched analyses (HR 1.24, 95 % CI 0.99-1.55). Five-year risk of HF was also similar (HR 1.09; 0.66-1.791.4 % for dd AC-P and 1.3 % for FEC-D and, p = 0.72). Treatment with FEC-D was significantly associated with ER visits and hospital admissions (p < 0.0001). The risks of leukemia were low and similar among the 3 groups (AC-P: 0.34 %, FEC-D: 0.08 %, dd AC-P: 0.12 %; p = 0.09). Although the efficacy of the three regimens was similar to that observed in randomized trials, we report higher toxicity with the use of these regimens in clinical practice. This was especially concerning for the docetaxel-containing regimen.
机译：这项研究的目的是比较接受（1）阿霉素（A），环磷酰胺（C）+紫杉醇（P），（2）氟尿嘧啶（F）治疗的早期乳腺癌（BC）妇女的生存率和不良事件风险），表柔比星（E），环磷​​酰胺（C）+多西他赛（D）或（3）剂量密集的AC-P。回顾性队列研究包括2003年至2009年在安大略省诊断的BC省I-III期切除患者，通过行政数据库的链接进行了研究，研究对象包括8462名年龄在千分之内的女性。主要结局是总体生存期（OS）。次要结果是急诊室/医院住院，心力衰竭（HF）和白血病。接受FEC-D治疗的女性有4710名，接受AC-P的女性有2065名，接受了dd AC-P的女性有1687名。每种方案的调整后5年OS分别为92.1％，87.7和90.3％（p = 0.0006）。在倾向评分匹配分析中，FEC-D和dd AC-P的OS没有差异（HR 1.24，95％CI 0.99-1.55）。五年的HF风险也相似（HR 1.09; dd AC-P为0.66-1.791.4％，FEC-D为1.3％，p = 0.72）。 FEC-D治疗与急诊就诊和入院率显着相关（p <0.0001）。患白血病的风险较低，三组之间相似（AC-P：0.34％，FEC-D：0.08％，dd AC-P：0.12％; p = 0.09）。尽管这三种方案的疗效与随机试验中观察到的相似，但我们报告在临床实践中使用这些方案具有更高的毒性。对于含多西他赛的方案，这尤其令人担忧。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号